

1. DATE ISSUED MM/DD/YYYY 03/16/2020		1a. SUPERSEDES AWARD NOTICE dated 03/13/2020 except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA NO. 93.354 - Public Health Emergency Response: Cooperative Agreement for Emergency Response: Public Health Crisis Response			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 6 NU90TP922071-01-02 Formerly		5. TYPE OF AWARD Other	
4a. FAIN NU90TP922071		5a. ACTION TYPE Post Award Amendment	
6. PROJECT PERIOD MM/DD/YYYY From 03/05/2019		Through 03/15/2021	
7. BUDGET PERIOD MM/DD/YYYY From 03/05/2019		Through 03/15/2021	
8. TITLE OF PROJECT (OR PROGRAM) Cooperative Agreement for Emergency Response: Public Health Crisis Response			

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention**

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD
AUTHORIZATION (Legislation/Regulations)
311(c)(1) of the Public Health Service Act (42 USC § 243(c)(1))

9a. GRANTEE NAME AND ADDRESS Public Health, California Department of 1615 Capitol Ave Sacramento, CA 95814-5015		9b. GRANTEE PROJECT DIRECTOR Ms. Tricia Blocher 1615 Capitol Ave Sacramento, CA 95814-5015 Phone: 916-650-6416	
10a. GRANTEE AUTHORIZING OFFICIAL Ms. Susan Fanelli 1615 CAPITOL AVE SACRAMENTO, CA 95814-5015 Phone: 916-650-6710		10b. FEDERAL PROJECT OFFICER Justin Alexander 1600 Clifton Rd Atlanta, GA 30333 Phone: 404-498-0979	

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)				12. AWARD COMPUTATION			
I Financial Assistance from the Federal Awarding Agency Only				a. Amount of Federal Financial Assistance (from item 11m) 41,206,709.00			
II Total project costs including grant funds and all other financial participation <input type="checkbox"/> I				b. Less Unobligated Balance From Prior Budget Periods 0.00			
a. Salaries and WageS 0.00				c. Less Cumulative Prior Award(s) This Budget Period 0.00			
b. Fringe Benefits 0.00				d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 41,206,709.00			
c. Total Personnel Costs 0.00				13. Total Federal Funds Awarded to Date for Project Period 41,206,709.00			
d. Equipment 0.00				14. RECOMMENDED FUTURE SUPPORT			
e. Supplies 0.00				(Subject to the availability of funds and satisfactory progress of the project):			
f. Travel 0.00				YEAR TOTAL DIRECT COSTS YEAR TOTAL DIRECT COSTS			
g. Construction 0.00				a. 2 b. 3 c. 4 d. 5 e. 6 f. 7			
h. Other 41,206,709.00				15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:			
i. Contractual 0.00				a. DEDUCTION			
j. TOTAL DIRECT COSTS → 41,206,709.00				b. ADDITIONAL COSTS			
k. INDIRECT COSTS 0.00				c. MATCHING			
l. TOTAL APPROVED BUDGET 41,206,709.00				d. OTHER RESEARCH (Add / Deduct Option)			
m. Federal Share 41,206,709.00				e. OTHER (See REMARKS)			
n. Non-Federal Share 0.00				16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDOING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:			
				a. The grant program legislation			
				b. The grant program regulations.			
				c. This award notice including terms and conditions, if any, noted below under REMARKS.			
				d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.			
				In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.			

REMARKS (Other Terms and Conditions Attached - Yes No)
Phase II (Component B) COVID-19 Response

GRANTS MANAGEMENT OFFICIAL:

Tiffany Mannings, Grants Management Officer
2960 Brandywine Rd
Mailstop E01
Atlanta, GA 30341-5509
Phone: 770.488.2515

17.OBJ CLASS 41.51	18a. VENDOR CODE 1743204993A1	18b. EIN 743204993	19. DUNS 799150615	20. CONG. DIST. 06
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 0-9390EPX	b. 20NU90TP922071CV	c. TP	d. \$41,206,709.00	e. 75-2022-0943
22. a.	b.	c.	d.	e.
23. a.	b.	c.	d.	e.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 03/16/2020
GRANT NO. 6 NU90TP922071-01-02	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 03/16/2020
GRANT NO. 6 NU90TP922071-01-02	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
03/05/2019	03/04/2020	Annual	06/02/2020
03/05/2020	09/04/2020	Annual	12/03/2020

AWARD ATTACHMENTS

California Department of Public Health

6 NU90TP922071-01-02

1. FINAL T&C

TERMS AND CONDITIONS OF AWARD

Incorporation:

In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-TP18-1802, entitled “Cooperative Agreement for Emergency Response: Public Health Crisis Response” and the **COVID-19 Crisis Response Cooperative Agreement – Component A and B Supplemental Funding Guidance**, which is hereby made a part of this non-research award, hereinafter referred to as the Notice of Award (NoA).

Component B COVID-19 Funding: Additional funding is approved for Component B **COVID-19 Crisis Response** activities, as described in the supplemental funding guidance. The funding listed on page 1 of the NoA is cumulative and includes previously awarded COVID-19 funds. This also extends the budget and project period end date to twelve (12) months from the date of this Notice of Award (NoA).

Pre-Award Costs: Pre-award costs dating back to January 20, 2020 – when CDC first activated its Emergency Operations Center (EOC) – and directly related to the COVID-10 outbreak response are allowable.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees’ time and effort.

Budget Revision Requirement: Jurisdictions must submit revised budgets (SF-424A) and budget narratives (budget narrative template provided) by **April 20, 2020**. These documents must be submitted to CDC along with a letter on jurisdiction agency letterhead with signatures from the jurisdiction’s preparedness director, laboratory director, and state epidemiologist (or their designees) indicating all have provided input into plans, strategies, and investment priorities. Jurisdictions must submit all documents via GrantSolutions.

Revised Work Plan: Jurisdictions must submit revised work plans (work plan template provided) as a grants note (labeled “[Jurisdiction] COVID-19 Work Plan”) in GrantSolutions no later than **May 4, 2020**.

Additional Reporting:

- Monthly progress reports on status of timelines, goals, and objectives as defined by CDC in approved work plans.
- Monthly fiscal reports as defined in REDCap (beginning 60 days after NOAs are issued).
- Performance measure data (see Section VIII. Performance Measures).
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.

Additional Term and Condition:

- A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and

Response Supplemental Appropriations Act, 2020 (P.L. 116-123) agrees to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

If recipient disburses any funds received pursuant to this award to a local jurisdiction, recipient shall ensure that the local jurisdiction complies with the terms and conditions of this award.

- Consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322) and the purpose of this award and the underlying funding, Recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds. CDC will specify in further guidance and directives what is encompassed by this requirement.

Unallowable Costs:

- Research
- Clinical care (except as otherwise noted in Domain 5 and as may be provided in further guidance from CDC)
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
 -
- All unallowable costs cited in CDC-RFA-TP18-1802 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1- 800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The UPDATED grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System

(FAPIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Damond Barnes, Grants Management Specialist
Centers for Disease Control and Prevention
Branch IV
2939 Flowers Road
Atlanta, GA 30341
Email: xhp5@cdc.gov

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376 and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

CDC, Office of Grants Services
Damond Barnes, Grants Management Specialist
Centers for Disease Control and Prevention

Branch IV

2939 Flowers Road
Atlanta, GA 30341
Email: xhp5@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

Tiandra M. Thornton, Project Officer
Centers for Disease Control and Prevention
Atlanta, Georgia
Telephone: 404-498-5495
Email: lgy5@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Tiffany Mannings, Grants Management Officer
Centers for Disease Control and Prevention

Branch IV

2939 Flowers Road
Atlanta, GA 30341
Email: yuo7@cdc.gov

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.